CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Dr. Reddy's Laboratories announces the launch of Doxercalciferol Injection
DSIJ Intelligence
/ Categories: Trending, DSIJ News

Dr. Reddy's Laboratories announces the launch of Doxercalciferol Injection

Dr. Reddy's has launched Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, a therapeutic generic equivalent of Hectorol (doxercalciferol) Injection 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, which has been approved by the U.S. Food and Drug Administration (USFDA).

Doxercalciferol, the active ingredient is a synthetic vitamin D2 analog that undergoes metabolic activation. Doxercalciferol Injectionis indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

According to IQVIA Health, the Hectorol Injection 4 mcg/2 ml (2 mcg/ml) single-dose vials and multiple-dose vials brand and generics had the sales of approximately US$138 mn MAT in the U.S for the most recent twelve months ending in September 2019. Hectorol is a trademark of Sanofi-Aventis US LLC.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, which provides affordable and innovative medicines for healthier lives. The company offers a portfolio of products and services, including APls, custom pharmaceutical services, generics, biosimilars, and differentiated formulations through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

On Friday, the stock of the company closed at Rs. 2,866, down by 0.43 per cent or Rs. 12.35 per share. The 52-week high is Rs. 2,965.20 and 52-week low is Rs. 2,065.30 on BSE.

Previous Article IPO Analysis: CSB Bank
Next Article Lupin launches connected Smart Device-Adhero in India
Print
2241 Rate this article:
3.5
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR